08:45 AM EST, 11/03/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday it plans to build a $3 billion manufacturing facility in Katwijk, the Netherlands, in a move to expand its capacity to produce oral medicines.

The new facility, to be located in Leiden Bio Science Park, will be one of the manufacturing sites for orforglipron, Lilly's oral, small molecule GLP-1 receptor agonist that it plans to submit to global regulatory agencies for obesity by the end of the year, the company said.